Blood:VWF清除和FVIII结合的遗传决定因素修饰血友病患者的FVIII药代动力学

2019-07-29 MedSci MedSci原创

在A型血友病患者中,VIII因子(FVIII)的药代动力学特性显示出高度的患者间变异性。虽然既往研究表明年龄、体重指数、VWF抗原水平和ABO血型状况都会影响FVIII的药代动力学,但它们并不能解释所有观察到的差异。在本研究中,研究人员对43名A型血友病患儿的FVIII药物代谢动力学特征的遗传决定因素进行分析。

中心点:

VWF基因变异可修饰FVIII结合位点,影响FVIII PK

VWF-FVIII的清除受体变异可影响FVIII PK

摘要:

在A型血友病患者中,VIII因子(FVIII)的药代动力学特性显示出高度的患者间变异性。虽然既往研究表明年龄、体重指数、VWF抗原水平和ABO血型状况都会影响FVIII的药代动力学,但它们并不能解释所有观察到的差异。在本研究中,研究人员对43名A型血友病患儿的FVIII药物代谢动力学特征的遗传决定因素进行分析。

研究人员发现VWF:Ag和VWFpp/VWF:Ag与FVIII半衰期相关,但VWFpp无其无关。在非O型血个体中,VWFpp/VWF:Ag与FVIII半衰期负相关,但O型血个体中未观察到此相关性,提示ABO血型修饰的VWF半衰期对FVIII药代动力学有较强的调节作用。

VWF的FVIII结合活性与FVIII半衰期呈正相关,在VWF:FVIIIB降低而VWF:Ag未降低的患者中,发现了罕见或低频率的、非同义的VWF变异p.(Arg826Lys)和p.(Arg852Glu)。既往已明确与血浆VWF和FVIII水平有关的VWF、CLEC4M和STAB2位点的常见变异均与FVIII的药代动力学特征有关。

综上所述,这些研究描述了VWF清除和ABO糖基化修饰儿童人群中FVIII药代动力学的机制基础。此外,本研究是第一个明确非VWF和ABO变异可修饰A型血友病患儿的FVIII药物代谢动力学的研究。

原始出处:

Laura L. Swystun,et al.
Genetic determinants of VWF clearance and FVIII-binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.Blood 2019 :blood.2019000190; doi: https://doi.org/10.1182/blood.2019000190

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671037, encodeId=c8c316e1037de, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Thu Dec 05 23:02:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916133, encodeId=c0cf1916133ce, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 10 11:02:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715781, encodeId=d5d81e157811f, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Aug 12 03:02:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666735, encodeId=90711666e35a8, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Jun 16 04:02:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351275, encodeId=d53613512e596, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372598, encodeId=adfb13e25983f, content=<a href='/topic/show?id=afaa185637c' target=_blank style='color:#2F92EE;'>#vWF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18563, encryptionId=afaa185637c, topicName=vWF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569368, encodeId=2ae01569368ca, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370468, encodeId=13ff3e04685a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 29 22:38:31 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671037, encodeId=c8c316e1037de, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Thu Dec 05 23:02:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916133, encodeId=c0cf1916133ce, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 10 11:02:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715781, encodeId=d5d81e157811f, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Aug 12 03:02:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666735, encodeId=90711666e35a8, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Jun 16 04:02:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351275, encodeId=d53613512e596, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372598, encodeId=adfb13e25983f, content=<a href='/topic/show?id=afaa185637c' target=_blank style='color:#2F92EE;'>#vWF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18563, encryptionId=afaa185637c, topicName=vWF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569368, encodeId=2ae01569368ca, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370468, encodeId=13ff3e04685a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 29 22:38:31 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
    2019-09-10 juliusluan78
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671037, encodeId=c8c316e1037de, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Thu Dec 05 23:02:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916133, encodeId=c0cf1916133ce, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 10 11:02:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715781, encodeId=d5d81e157811f, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Aug 12 03:02:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666735, encodeId=90711666e35a8, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Jun 16 04:02:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351275, encodeId=d53613512e596, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372598, encodeId=adfb13e25983f, content=<a href='/topic/show?id=afaa185637c' target=_blank style='color:#2F92EE;'>#vWF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18563, encryptionId=afaa185637c, topicName=vWF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569368, encodeId=2ae01569368ca, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370468, encodeId=13ff3e04685a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 29 22:38:31 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671037, encodeId=c8c316e1037de, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Thu Dec 05 23:02:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916133, encodeId=c0cf1916133ce, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 10 11:02:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715781, encodeId=d5d81e157811f, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Aug 12 03:02:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666735, encodeId=90711666e35a8, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Jun 16 04:02:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351275, encodeId=d53613512e596, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372598, encodeId=adfb13e25983f, content=<a href='/topic/show?id=afaa185637c' target=_blank style='color:#2F92EE;'>#vWF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18563, encryptionId=afaa185637c, topicName=vWF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569368, encodeId=2ae01569368ca, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370468, encodeId=13ff3e04685a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 29 22:38:31 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
    2020-06-16 fengyqf
  5. [GetPortalCommentsPageByObjectIdResponse(id=1671037, encodeId=c8c316e1037de, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Thu Dec 05 23:02:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916133, encodeId=c0cf1916133ce, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 10 11:02:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715781, encodeId=d5d81e157811f, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Aug 12 03:02:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666735, encodeId=90711666e35a8, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Jun 16 04:02:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351275, encodeId=d53613512e596, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372598, encodeId=adfb13e25983f, content=<a href='/topic/show?id=afaa185637c' target=_blank style='color:#2F92EE;'>#vWF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18563, encryptionId=afaa185637c, topicName=vWF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569368, encodeId=2ae01569368ca, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370468, encodeId=13ff3e04685a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 29 22:38:31 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1671037, encodeId=c8c316e1037de, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Thu Dec 05 23:02:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916133, encodeId=c0cf1916133ce, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 10 11:02:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715781, encodeId=d5d81e157811f, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Aug 12 03:02:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666735, encodeId=90711666e35a8, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Jun 16 04:02:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351275, encodeId=d53613512e596, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372598, encodeId=adfb13e25983f, content=<a href='/topic/show?id=afaa185637c' target=_blank style='color:#2F92EE;'>#vWF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18563, encryptionId=afaa185637c, topicName=vWF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569368, encodeId=2ae01569368ca, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370468, encodeId=13ff3e04685a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 29 22:38:31 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
    2019-07-31 sunmin0219
  7. [GetPortalCommentsPageByObjectIdResponse(id=1671037, encodeId=c8c316e1037de, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Thu Dec 05 23:02:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916133, encodeId=c0cf1916133ce, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 10 11:02:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715781, encodeId=d5d81e157811f, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Aug 12 03:02:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666735, encodeId=90711666e35a8, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Jun 16 04:02:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351275, encodeId=d53613512e596, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372598, encodeId=adfb13e25983f, content=<a href='/topic/show?id=afaa185637c' target=_blank style='color:#2F92EE;'>#vWF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18563, encryptionId=afaa185637c, topicName=vWF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569368, encodeId=2ae01569368ca, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370468, encodeId=13ff3e04685a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 29 22:38:31 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
    2019-07-31 zhangyxzsh
  8. [GetPortalCommentsPageByObjectIdResponse(id=1671037, encodeId=c8c316e1037de, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Thu Dec 05 23:02:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916133, encodeId=c0cf1916133ce, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Sep 10 11:02:00 CST 2019, time=2019-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715781, encodeId=d5d81e157811f, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon Aug 12 03:02:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666735, encodeId=90711666e35a8, content=<a href='/topic/show?id=df6a8e287d7' target=_blank style='color:#2F92EE;'>#药代#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87287, encryptionId=df6a8e287d7, topicName=药代)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccf26064950, createdName=fengyqf, createdTime=Tue Jun 16 04:02:00 CST 2020, time=2020-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351275, encodeId=d53613512e596, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87289, encryptionId=9ac28e2893e, topicName=药代动力学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372598, encodeId=adfb13e25983f, content=<a href='/topic/show?id=afaa185637c' target=_blank style='color:#2F92EE;'>#vWF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18563, encryptionId=afaa185637c, topicName=vWF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569368, encodeId=2ae01569368ca, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Wed Jul 31 13:02:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370468, encodeId=13ff3e04685a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 29 22:38:31 CST 2019, time=2019-07-29, status=1, ipAttribution=)]
    2019-07-29 1ddf0692m34(暂无匿称)

    学习了,长知识

    0

相关资讯

Blood:VWF的肝素结合结构域可结合生长因子促进新生血管形成

中心点:VWF的肝素结合结构域可与生长因子结合。在伤口愈合过程中,VWF的肝素结合结构域与生长因子协同促血管生成。摘要:在伤口愈合过程中,生长因子(GFs)通过结合创面微环境中的细胞外基质成分,调控其分布、有效性和信号传导。细胞外基质蛋白可通过结合GFs调节血管生成、促进伤口愈合。血管内皮细胞(ECs)在血浆和内皮下基质中释放的止血蛋白血管假性血友病因子(VWF)可调节血管生成;这种功能与VWF缺

Blood:如何治疗低VWF水平!

血浆血管性血友病因子(VWF)的部分定量不足,是导致血管性血友病的主要因素;血管性血友病是最常见的出血性疾病。国际共识指南推荐血浆VWF:Ag水平降低和有出血表型的患者应被视为两个不同的亚集。首先,血浆VWF水平明显降低(<30IU/dL)的患者通常有明显的出血表型,应被归类为“I型VWD”。相反,血浆VWF:Ag水平中度降低(30-50IU/dL)的患者应被归为“低VWF水平”。低VWF水

Blood:ADAMTS13物种间高度保守的变构调节!

中心点:在脊椎动物中,ADAMTS13的结构异常多变。在功能上,完全变构调节型ADAMTS13仅需要不超过3次的远端血小板反应蛋白重复。摘要:金属蛋白酶ADAMTS13可通过裂解富含血小板的血栓中的血管性血友病因子(VWF)来预防微血管血栓形成,而裂解依赖于底物VWF对ADAMTS13的变构激活。人ADAMTS13具有一个短的前导肽、金属蛋白酶(M)、解联蛋白 (D)、血小板反应蛋白-1 (T)、

Blood:血栓性微血管病变是BCR-ABL1酪氨酸激酶抑制剂帕纳替尼引发心血管毒性的原因之一

中心点:帕纳替尼疗法可导致VWF介导的血小板黏附至微血管内皮细胞。帕纳替尼依赖性的微血管病变可降低节段性的LV功能异常。摘要:第三代酪氨酸激酶抑制剂(TKI)帕纳替尼可有效治疗耐药性慢性粒细胞白血病,但急性缺血事件发生率高,限制了其临床应用。而且,造成这些事件的病理生理机制尚不明确。Yllka Latifi等人推测帕纳替尼可引发一种血管内皮病,涉及内皮相关的血管性血友病因子(VWF)过量和继发性血

Blood:血管性血友病因子(VWF)Tyr2561等位基因是一种功能获得性突变,会增加年青人的心肌梗死风险

中心点:VWF p.Phe2561Tyr是一个功能获得性突变,可增加VWF和血小板相互作用的灵敏性。VWF p.Phe2561Tyr与复发性心肌梗死相关,特别是发生年轻女性中的。摘要:常见的血管性血友病因子(VWF)突变p.Phe2561Tyr位于C4结构域域,该结构域也包含结合血小板GPIIb/IIIa的RGD序列。为探究该突变对止血的潜在影响,研究人员对865位冠状动脉疾病(CAD)患者、91

Blood:Weibel-Palade小体的邻近蛋白质组学揭示VWF分泌的新调控因子

Weibel-Palade小体(WPB)是一种特殊的内皮细胞分泌细胞器,可储存调节血管止血和局部炎症的因子。内皮细胞活化触发WPB快速分泌,导致白细胞滚动和血小板捕获相关的粘附分子(分别是P-选择素和血管性血友病因子[VWF])呈现于细胞表面。虽然已知WPB是一种重要的分泌细胞器,但尚无对WPB有关因素的全面了解。